Akebia Therapeutics Inc (AKBA) concluded trading on Wednesday at a closing price of $3.63, with 4.62 million shares of worth about $16.76 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 86.15% during that period and on July 02, 2025 the price saw a gain of about 1.68%. Currently the company’s common shares owned by public are about 261.64M shares, out of which, 251.57M shares are available for trading.
Stock saw a price change of -1.36% in past 5 days and over the past one month there was a price change of 11.69%. Year-to-date (YTD), AKBA shares are showing a performance of 255.88% which increased to 91.05% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.91 but also hit the highest price of $4.08 during that period. The average intraday trading volume for Akebia Therapeutics Inc shares is 5.07 million. The stock is currently trading -1.05% below its 20-day simple moving average (SMA20), while that difference is up 19.43% for SMA50 and it goes to 69.85% higher than SMA200.
Akebia Therapeutics Inc (NASDAQ: AKBA) currently have 261.64M outstanding shares and institutions hold larger chunk of about 36.57% of that.
The stock has a current market capitalization of $953.37M and its 3Y-monthly beta is at 0.97. It has posted earnings per share of -$0.22 in the same period. It has Quick Ratio of 2.02 while making debt-to-equity ratio of 8.39. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AKBA, volatility over the week remained 4.94% while standing at 6.42% over the month.
Stock’s fiscal year EPS is expected to rise by 80.61% while it is estimated to increase by 215.62% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on June 04, 2025 offering a Buy rating for the stock and assigned a target price of $8 to it. Coverage by Leerink Partners stated Akebia Therapeutics Inc (AKBA) stock as an Outperform in their note to investors on April 28, 2025, suggesting a price target of $7 for the stock. On April 01, 2025, Jefferies Initiated their recommendations, while on November 29, 2023, BTIG Research Resumed their ratings for the stock with a price target of $4. Stock get a Buy rating from H.C. Wainwright on August 28, 2023.
